D
Dorota Zarębska-Michaluk
Researcher at Jan Kochanowski University
Publications - 128
Citations - 1085
Dorota Zarębska-Michaluk is an academic researcher from Jan Kochanowski University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 76 publications receiving 561 citations. Previous affiliations of Dorota Zarębska-Michaluk include Cornell University.
Papers
More filters
Journal ArticleDOI
Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
Robert Flisiak,Ewa Janczewska,Marta Wawrzynowicz-Syczewska,Jerzy Jaroszewicz,Dorota Zarębska-Michaluk,Khalil Nazzal,Beata Bolewska,Jolanta Białkowska,Hanna Berak,Katarzyna Fleischer-Stępniewska,Krzysztof Tomasiewicz,Kornelia Karwowska,K. Rostkowska,Anna Piekarska,Olga Tronina,Grzegorz Madej,Aleksander Garlicki,M. Lucejko,Arkadiusz Pisula,Ewa Karpińska,Wiesław Kryczka,Alicja Wiercińska-Drapało,Iwona Mozer-Lisewska,Maciej Jabłkowski,Andrzej Horban,Brygida Knysz,Magdalena Tudrujek,Waldemar Halota,K. Simon +28 more
TL;DR: Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy have shown high sustained virologic response (SVR) rates and good tolerability in most patient populations in pre‐registration studies.
Journal ArticleDOI
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of March 31, 2020.
Robert Flisiak,Andrzej Horban,Jerzy Jaroszewicz,Dorota Kozielewicz,Agnieszka Mastalerz-Migas,Radosław Owczuk,Miłosz Parczewski,Małgorzata Pawłowska,Anna Piekarska,Krzysztof Simon,Krzysztof Tomasiewicz,Dorota Zarębska-Michaluk +11 more
TL;DR: Mortality rates vary from country to country and depend on the quality of health care, in particular the equipment and the availability of intensive care units, but also on many unknown human genetic factors and / or virus genetic mutability.
Journal ArticleDOI
Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022.
Robert Flisiak,Andrzej Horban,Jerzy Jaroszewicz,Dorota Kozielewicz,Agnieszka Mastalerz-Migas,Radosław Owczuk,Miłosz Parczewski,Małgorzata Pawłowska,Anna Piekarska,Krzysztof Simon,Krzysztof Tomasiewicz,Dorota Zarębska-Michaluk +11 more
TL;DR: Anakinra, an antagonist of interleukin 1 receptors, has been added as a treatment option in advanced stages of the disease, and the recommended daily dose of glucocorticosteroids used in the most severe forms of COVID-19 has been increased.
Journal Article
Distribution of HCV genotypes in Poland.
Anatol Panasiuk,Robert Flisiak,Iwona Mozer-Lisewska,Agnieszka Adamek,Malgorzata Tyczyno,Waldemar Halota,Małgorzata Pawłowska,Janusz Stańczak,Hanna Berak,Marta Wawrzynowicz-Syczewska,Anna Boroń-Kaczmarska,Tadeusz Wojciech Łapiński,Anna Grzeszczuk,Anna Piekarska,Krzysztof Tomasiewicz,Maciej Jabłkowski,Wiesław Kryczka,Dorota Zarębska-Michaluk,Piotr M. Stępień,Aleksander Garlicki,Joanna Kozłowska,Alicja Wiercińska-Drapało,Ewelina Zasik,Waldemar Mazur,Bozena Dobracka,Witold Dobracki,Krzysztof Simon,Józef Ryżko,Joanna Pawłowska,Katarzyna Dzierżanowska-Fangrat,Danuta Januszkiewicz-Lewandowska,Leszek Szenborn,Izabela Zaleska,Maria Rokitka,Elzbieta Strawińska,Katarzyna Balinowska,Tomasz Smiatacz,Piotr Stalke,Katarzyna Sikorska,Anna Lakomy,Maciej Zdrojewski,Anna Lachowicz +41 more
TL;DR: There is a geographic variability of HCV genotypes prevalence in Poland, and increase ofHCV G1 infections and decrease of G3 and G4 were observed in the last 10 years, as well as in populations of HBV and HIV co-infections.
Journal ArticleDOI
Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study.
Krzysztof Tomasiewicz,Anna Piekarska,Justyna Stempkowska-Rejek,Sylwia Serafińska,Aleksandra Gawkowska,Miłosz Parczewski,Jolanta Niścigorska-Olsen,Tadeusz Wojciech Łapiński,Dorota Zarębska-Michaluk,Justyna D. Kowalska,Andrzej Horban,Robert Flisiak +11 more
TL;DR: Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients.